The medical management of primary sclerosing cholangitis

MedGenMed Medscape General Medicine

Volumn 10, Issue 3, 2008, Pages

  Michaels, Anthony ^a   Levy, Cynthia ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; AZATHIOPRINE; BEZAFIBRATE; BUDESONIDE; CLADRIBINE; COLCHICINE; COLESTYRAMINE; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; FLUVOXAMINE; METHOTREXATE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NALOXONE; NICOTINE; ONDANSETRON; PENICILLAMINE; PENTOXIFYLLINE; PIRFENIDONE; PLACEBO; PREDNISOLONE; PREDNISONE; RIFAMPICIN; SALAZOSULFAPYRIDINE; SERTRALINE; STEROID; TACROLIMUS; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; CHOLAGOGUE;

ABDOMINAL PAIN; ALPHA TOCOPHEROL DEFICIENCY; ARTHRALGIA; ATAXIA; CLINICAL TRIAL; COLON TUMOR; COMBINATION CHEMOTHERAPY; DEFECATION; DIARRHEA; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOSCOPIC THERAPY; EVIDENCE BASED MEDICINE; FATIGUE; HEARTBURN; HUMAN; INSOMNIA; LIFESTYLE MODIFICATION; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE DRUG DOSE; NAUSEA; NONHUMAN; OSTEOPOROSIS; OUTCOME ASSESSMENT; PARESTHESIA; PRIMARY SCLEROSING CHOLANGITIS; PRURITUS; QUALITY OF LIFE; RETINOL DEFICIENCY; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMIC DISEASE; TREATMENT DURATION; TREMOR; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; VISUAL HALLUCINATION; VITAMIN D DEFICIENCY; VOMITING; BILIARY CIRRHOSIS; CLINICAL PRACTICE; METHODOLOGY; SCLEROSING CHOLANGITIS;

CHOLAGOGUES AND CHOLERETICS; CHOLANGITIS, SCLEROSING; HUMANS; LIVER CIRRHOSIS, BILIARY; LIVER TRANSPLANTATION; PHYSICIAN'S PRACTICE PATTERNS; URSODEOXYCHOLIC ACID;

EID: 42349093622     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Tischendorf JJ, Hecker H, Kruger M, Manns MP, Meier PN. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol. 2007;102:107-114.
2. LaRusso NF, Shneider BL, Black D, et al. Primary sclerosing cholangitis: summary of a workshop. Hepatology. 2006;44:746-764.
3. Angulo P, Lindor KD. Primary biliary cirrhosis and primary sclerosing cholangitis. Clin Liver Dis. 1999;3:529-570.
4. Levy C, Lindor KD. Primary sclerosing cholangitis: epidemiology, natural history, and prognosis. Sernin Liver Dis. 2006;26:22-30.
5. Lee YM, Kaplan MM; Practice Guideline Committee of the American College of Gastroenterology. Management of primary sclerosing cholangitis. Am J Gastroenterol. 2002;97:528-534.
6. Cullen SN, Chapman RW. The medical management of primary sclerosing cholangitis. Semin Liver Dis. 2006;26:52-61.
7. Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid mechanisms of action and clinical use in hepatobiliary disorders. J Hepatol. 2001;35:134-146.
8. Poupon R, Chretien Y, Poupon RE, Ballet F, Calmus Y, Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet. 1987;1(8537):834-1836.
9. Podda M, Ghezzi C, Battezzati PM, et al. Ursodeoxycholic acid for chronic liver diseases. J Clin Gastroenterol. 1988;10 Suppl 2:S25-S31.
10. Mitchell SA, Chapman RW. The management of primary sclerosing cholangitis. Aliment Pharmacol Ther. 1997;11:33-43.
11. Podda M, Ghezzi C, Battezzati PM, et al. Effect of different doses of ursodeoxycholic acid in chronic liver disease. Dig Dis Sci. 1989;34(12 Suppl):59S-65S.
12. Chazouilleres O, Poupon R, Capron JP, et al. Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol. 1990;11:120-123.
13. Hayashi H, Higuchi T, Ichimiya H, Hishida N, Sakamoto N. Asymptomatic primary sclerosing cholangitis treated with ursodeoxycholic acid. Gastroenterology. 1990;99:533-535.
14. O'Brien CB, Senior JR, Arora-Mirchandani R, Batta AK, Salen G. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. Hepatology. 1991;14:838-847.
15. Beuers U, Spengler U, Kruis W. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology. 1992;16:707-714.
16. van Milligen de Wit AW, Kuiper H, Camoglio L, et al. Does ursodeoxycholic acid mediate immunomodulatory and anti-inflammatory effects in patients with primary sclerosing cholangitis? Eur J Gastroenterol Hepatol. 1999;11:129-136.
17. Stiehl A, Walker S, Stiehl L, Rudolph G, Hofmann WJ, Theilmann L. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol. 1994;20:57-64.
18. De Maria N, Colantoni A, Rosenbloom E, Van Thiel DH. Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period. Hepatogastroenterology. 1996;43:1472-1479.
19. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-UrsodeQxycholic Acid Study Group N Engl J Med. 1997;336:691-695.
20. van Hoogstraten HJ, Wolfhagen FH, van de Meeberg PC, et al. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses. J Hepatol. 1998;29:417-423.
21. Okolicsanyi L, Groppo M, Floreani A, et al. Treatment of primary sclerosing cholangitis with low-dose ursodeoxycholic acid: results of a retrospective Italian multicentre survey. Dig Liver Dis. 2003;35:325-331.
22. Harnois DM, Angulo P, Jorgensen RA, Larusso NF, Lindor KD. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol. 2001;96:1558-1562.
23. Rost D, Rudolph G, Kloeters-Plachky P, Stiehl A. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis. Hepatology. 2004;40:693-698.
24. Mitchell SA, Bansi DS, Hunt N, Von Bergmann K,, Fleming KA, Chapman RW. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology. 2001;121:900-907.
25. Olsson R, Boberg KM, de Muckadell OS, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology. 2005;129:1464-1472.
26. Tung BY, Emond MJ, Haggitt RC, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med. 2001;134:89-95.
27. Sjoqvist U, Tribukait B, Ost A, Einarsson U, Oxelmark L, Lotberg K. Ursodeoxycholic acid treatment in IBD-patients with colorectal dysplasia and/or DNA-aneuploidy: a prospective, double-blind, randomized controlled pilot study. Anticancer Res. 2004;24:3121-3127.
28. Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology. 2003;124:889-893.
29. Oyama K, Shiota G, Ito H, Murawaki Y, Kawasaki H. Reduction of hepatocarcinogenesis by ursodeoxycholic acid in rats. Carcinogenesis. 2002;23:885-892.
30. Rudolph G, Kloeters-Plachky P, Rost D, Stiehl A. The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid. Eur J Gastroenterol Hepatol. 2007;19:487-491.
31. Lindor KD, Jorgensen RA, Anderson ML, Gores GJ, Hofmann AF, LaRusso NF. Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study. Am J Gastroenterol. 1996;91:511-515.
32. Schramm C, Schirmacher P, Helmreich-Becker I, Gerken G, zum Buschenfelde KH, Lohse AW. Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis. A case series. Ann Intern Med. 1999;131:943-946.
33. van Hoogstraten HJ, Vleggaar FP, Boland GJ, et al. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group. Am J Gastroenterol. 2000;95:2015-2022.
34. Sterling RK, Salvatori JJ, Luketic VA, et al. A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis. Aliment Pharmacol Ther. 2004;20:943-949.
35. Farkkila M, Karvonen AL, Nurmi H, et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology. 2004;40:1379-1386.
36. Stiehl A, Rudolph G, Sauer P, et al. Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study. J Hepatol. 1997;26:560-566.
37. Angulo P. Batts KP, Jorgensen RA, LaRusso NA, Lindor KD. Oral budesonide in the treatment of primary sclerosing cholangitis. Am J Gastroenterol. 2000;95:2333-2337.
38. Angulo P, Bharucha AE, Jorgensen RA, et al. Oral nicotine in treatment of primary sclerosing cholangitis: a pilot study. Dig Dis Sci. 1999;44:602-607.
39. Vleggaar FP, van Buuren HR, van Berge Henegouwen GP, Hop WC, van Erpecum KJ. No beneficial effects of transdemal nicotine in patients with primary sclerosing cholangitis: results of a randomized double-blind placebo-controlled cross-over study. Eur J Gastroenterol Hepatol. 2001;13:171-175.
40. Harries AD, Baird A, Rhodes J. Non-smoking: a feature of ulcerative colitis [Letter]. BMJ. 1982;284:706.
41. Loftus EV Jr, Sandborn WJ, Tremaine WJ, et al. Primary sclerosing cholangitis is associated with nonsmoking: a case-control study. Gastroenterology. 1996;110:1496-1502.
42. Van Erpecum KJ, Smits SJ, van de Meeberg PC, et al. Risk of primary sclerosing cholangitis is associated with nonsmoking behaviour. Gastroenterology. 1996;110:1503-1506.
43. Kita R, Kita-Sasai Y, Hanaoka I, et al. Beneficial effect of bezafibrate on primary sclerosing cholangitis (three case reports). Am J Gastroenterol. 2002;97:1849-1851.
44. Kurihara T, Maeda A, Shigemoto M, Yamashita K, Kamatani N. Efficacy of bezafibrate in a patient with primary sclerosing cholangitis. J Gastroenterol. 2003;38:300-301.
45. Kurihara T, Furukawa M, Tsuchiya M, et al. Effect of bezafibrate in the treatment of primary biliary cirhosis. Curr Ther Res. 2000;61:74-82.
46. Gondoh K, Ono T, Miyakoda K, et al. Bezafibrate alone is an effective first-line therapy for primary sclerosing cholangitis: a case report. Nippon Shokakibyo Gakkai Zasshi. 2006;103:643-649.
47. Knox TA, Kaplan MM. Treatment of primary sclerosing cholangitis with oral methotrexate. Am J Gastroenterol. 1991;86:546-552.
48. Knox TA, Kaplan MM. A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology. 1994;106:494-949.
49. Lee YM, Kaplan MM. Medical treatment of primary sclerosing cholangitis. J Hepatobiliary Pancreat Surg. 1999;6:361-365.
50. Olsson R, Broome U, Danielsson A, et al. Colchicine treatment of primary sclerosing cholangitis. Gastroenterology. 1995;108:1199-1203.
51. Lindor KD, Wiesner RH, Colwell LJ, Steiner B, Beaver S, LaRusso NF. The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. Am J Gastroenterol. 1991;86:57-61.
52. Van Thiel DH, Carroll P, Abu-Elmagd K, et al. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis results of an open-label preliminary trial. Am J Gastroenterol. 1995;90:455-459.
53. Talwalkar JA, Gossard AA, Keach JC, Jorgensen RA, Petz JL, Lindor RN. Tacrolimus for the treatment of primary sclerosing cholangitis. Liver Int. 2007;27:451-453.
54. Talwalkar JA, Angulo P, Keach JC, Petz JL, Jorgensen RA, Lindor KD. Mycophenolate mofetil for the treatment of primary sclerosing cholangitis. Am J Gastroenterol. 2005;100:308-312.
55. Lankarani KB. Mycophenolate mofetil for the treatment of primary sclerosing cholangitis. Aliment Pharmacol Ther. 2005;21:1279-1280.
56. LaRusso NF, Wiesner RH, Ludwig J, MacCarty RL, Beaver SJ, Zinsmeister AR. Prospective trial of penicilamine in primary sclerosing cholangitis. Gastroenterology. 1988;95:1036-1042.
57. Epstein MP, Kaplan MM. A pilot study of etanercept in the treatment of primary sclerosing cholangitis. Dig Dis Sci. 2004;49:1-4.
58. Bharucha AE, Jorgensen R, Lichtman SN, LaRusso NF, Lindor KD. A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis. Am J Gastroenterol. 2000;95:2338-2242.
59. Wagner A. Azathioprine treatment in primary sclerosing cholangitis. Lancet. 1971;2:663-664.
60. Angulo P, MacCarty RL, Sylvestre PB, et al. Pirfenidone in the treatment of primary sclerosing cholangitis. Dig Dis Sci. 2002;47:157-161.
61. Duchini A, Younossi ZM, Saven A, Bordin GM, Knowles HJ, Pockros PJ. An open-label pilot trial of cladibrine (2-cholordeoxyadenosine) in patients with primary sclerosing cholangitis. J Clin Gastroenterol. 2000;31:292-296.
62. Kyokane K, Ichihara T, Horisawa M, et al. Successful treatment of primary sclerosing cholangitis with cyclosporme and corticosteroid. Hepatogastroenterology. 1994;41:449-452.
63. Tada S, Ebinuma H, Saito H, Hibi T. Therapeutic benefit of sulfasalazine for patients with primary sclerosing cholangitis. J Gastroenterol. 2006;41:388-389.
64. Bjornsson E, Simren M, Olsson R, Chapman RW. Fatigue in patients with primary sclerosing cholangitis. Scand J Gastroenterol. 2004;39:961-968.
65. van Os E, van den Broek WW, Mulder PG, ter Borg PC, Bruijn JA, van Buuren HR. Depression in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol. 2007;46:1099-1103.
66. ter Borg PC, van Os E, van den Broek WW, Hansen BE, van Buuren HR. Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial. BMC Gastroenterol. 2004;4:i3.
67. Mayo MJ, Handem I, Saldana. S, Jacobe H, Getachew Y, Rush AJ. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology. 2007;45:666-674.
68. Jorgensen RA, Lindor KD, Sartin JS, LaRusso NF, Wiesner RH. Serum lipid and fat-soluble vitamin levels in primary sclerosing cholangitis. J Clin Gastroenterol. 1995;20:215-219.
69. Angulo P, Therneau TM, Jorgensen A, et al. Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression. J Hepatol. 1998;29:729-735.